Evommune starts Phase I trial of EVO756 for chronic spontaneous urticaria
EVO756 is a highly selective, potent small molecule antagonist of mas-related G-protein coupled receptor X2, designed to block…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
19 Jan 24
EVO756 is a highly selective, potent small molecule antagonist of mas-related G-protein coupled receptor X2, designed to block…
19 Jan 24
Both firms will work to understand rare tumours in patients treated with immune checkpoint inhibitors by characterising their…
18 Jan 24
The US FDA has cleared Amplia's Investigational New Drug (IND) Application for a clinical trial of narmafotinib in…
16 Jan 24
The IMPROVE-2 study enrolled 904 women and assigned randomly to the new drug therapy group against a monthly…
12 Jan 24
CSI is a clinical CRO that provides cost-effective clinical solutions through its team of experienced clinical research professionals…
12 Jan 24
Developed using Elicio’s lymph node targeting Amphiphile technology, ELI-002 is a structurally investigational therapeutic immunotherapy designed to target…
11 Jan 24
Under the alliance, Japanese Foundation for Cancer Research will become a valued member of Parexel's Global Site Alliance…
11 Jan 24
Collaboration Aims to Improve Patient Experience, Accessibility and Efficiency in Decentralized Clinical Trials
22 Dec 23
The collaboration combines Oncoshot's proficiency in data analysis and insights generation with Ablaze's recent expansion into data management…
20 Dec 23
The primary application of CorEvidence focuses on improving pharmacovigilance workflows and managing deliverables more effectively